Synthesis and anti-hepatocellular carcinoma activity of aminopyridinol–sorafenib hybrids

References

• Roskoski R, Jr. A historical overview of protein kinases and their targeted small molecule inhibitors. Pharmacol Res 2015;100:1–23.
   PubMed Web of Science ®Google Scholar
• Matallanas D, Birtwistle M, Romano D, et al. Raf family kinases: old dogs have learned new tricks. Genes Cancer 2011;2:232–60.
   PubMedGoogle Scholar
• Freeman AK, Ritt DA, Morrison DK. Effects of Raf dimerization and its inhibition on normal and disease-associated Raf signaling. Mol Cell 2013;49:751–8.
   PubMed Web of Science ®Google Scholar
• Santarpia L, Lippman SL, El-Naggar AK. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets 2012;16:103–19.
   PubMed Web of Science ®Google Scholar
• Haling JR, Sudhamsu J, Yen I, et al. Structure of the BRAF-MEK complex reveals a kinase activity independent role for BRAF in MAPK signaling. Cancer Cell 2014;26:402–13.
   PubMed Web of Science ®Google Scholar
• Holderfield M, Deuker MM, McCormick F, McMahon M. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer 2014;14:455–67.
   PubMed Web of Science ®Google Scholar
• Cheng L, Lopez-Beltran A, Massari F, et al. Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. Mod Pathol 2018;31:24–38.
   PubMed Web of Science ®Google Scholar
• Dienstmann R, Tabernero J. BRAF as a target for cancer therapy. Anticancer Agents Med Chem 2011;11:285–95.
   PubMed Web of Science ®Google Scholar
• Rissmann R, Hessel MHM, Cohen AF. Vemurafenib/dabrafenib and trametinib. Br J Clin Pharmacol 2015;80:765–7.
   PubMed Web of Science ®Google Scholar
• Gibney GT, Messina JL, Fedorenko IV, et al. Paradoxical oncogenesis – the long-term effects of BRAF inhibition in melanoma. Nat Rev Clin Oncol 2013;10:390–9.
   PubMed Web of Science ®Google Scholar
• Durrant DE, Morrison DK. Targeting the Raf kinases in human cancer: the Raf dimer dilemma. Br J Cancer 2018;118:3–8.
   PubMed Web of Science ®Google Scholar
• Adnane L, Trail PA, Taylor I, Wilhelm SM. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol 2006;407:597–612.
   PubMed Web of Science ®Google Scholar
• White PT, Cohen S. The discovery and development of sorafenib for the treatment of thyroid cancer. Expert Opin Drug Discov 2015;10:427–39.
   PubMed Web of Science ®Google Scholar
• Viegas C, Jr, Danuello A, da Silva BV, et al. Molecular hybridization: a useful tool in the design of new drug prototypes. Curr Med Chem 2007;14:1829–52.
   PubMed Web of Science ®Google Scholar
• Zhao Q, Huang G, Anticancer hybrids. In: M Decker, ed, Design of hybrid molecules for drug development. New York, NY: Elsevier B. V.; 2017. 193–218.
   Google Scholar
• Kerru N, Singh P, Koorbanally N, et al. Recent advances (2015–2016) in anticancer hybrids. Eur J Med Chem 2017;142:179–212.
   PubMed Web of Science ®Google Scholar
• Shah S, Lee C, Choi H, et al. 5-Hydroxy-7-azaindolin-2-one, a novel hybrid of pyridinol and sunitinib: design, synthesis and cytotoxicity against cancer cells. Org Biomol Chem 2016;14:4829–41.
   PubMed Web of Science ®Google Scholar
• Tourneau CL, Raymond E, Faivre S. Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST). Ther Clin Risk Manag 2007;3:341–8.
   PubMedGoogle Scholar
• Serwa R, Nam T-g, Valgimigli L, et al. Preparation and investigation of vitamin B6-derived aminopyridinol antioxidants. Chemistry 2010;16:14106–14.
   PubMed Web of Science ®Google Scholar
• Kim DG, Kang Y, Lee H, et al. 6-Amino-2,4,5-trimethylpyridin-3-ols: a new general synthetic route and antiangiogenic activity. Eur J Med Chem 2014;78:126–39.
   PubMed Web of Science ®Google Scholar
• Lee H, Banskota S, Kim DG, et al. Synthesis and antiangiogenic activity of 6-amido-2,4,5-trimethylpyridin-3-ols. Bioorg Med Chem Lett 2014;24:3131–6.
   PubMed Web of Science ®Google Scholar
• Banskota S, Gautam J, Regmi SC, et al. BJ-1108, a 6-amino-2,4,5-trimethylpyridin-3-ol analog, inhibits serotonin-induced angiogenesis and tumor growth through PI3K/NOX pathway. PLoS One 2016;11:e0148133.
   PubMed Web of Science ®Google Scholar
• Banskota S, Kang HE, Kim DG, et al. In vitro and in vivo inhibitory activity of 6-amino-2,4,5-trimethylpyridin-3-ols against inflammatory bowel disease. Bioorg Med Chem Lett 2016;26:4587–91.
   PubMed Web of Science ®Google Scholar
• Gautam J, Banskota S, Regmi SC, et al. Tryptophan hydroxylase 1 and 5-HT7 receptor preferentially expressed in triple-negative breast cancer promote cancer progression through autocrine serotonin signaling. Mol Cancer 2016;15:75.
   PubMed Web of Science ®Google Scholar
• imilshina M, Kang Y, Dahal I, et al. BJ-3105, a 6-alkoxypyridin-3-ol analog, impairs T cell differentiation and prevents experimental autoimmune encephalomyelitis disease progression. PLoS One 2017;12:e0168942.
   PubMed Web of Science ®Google Scholar
• Kang Y, Timilshina M, Nam TG, et al. BJ-1108, a 6-amino-2,4,5-trimethylpyridin-3-ol analogue, regulates differentiation of Th1 and Th17 cells to ameliorate experimental autoimmune encephalomyelitis. Biol Res 2017;50:8.
   PubMed Web of Science ®Google Scholar
• You Z, Timilshina M, Jeong BS, Chang JH. BJ-2266 ameliorates experimental autoimmune encephalomyelitis through down-regulation of the JAK/STAT signaling pathway. Eur J Immunol 2017;47:1488–500.
   PubMed Web of Science ®Google Scholar
• Bae D, Gautam J, Jang H, et al. Protective effects of 6-ureido/thioureido-2,4,5-trimethylpyridin-3-ols against 4-hydroxynonenal-induced cell death in adult retinal pigment epithelial-19 cells. Bioorg Med Chem Lett 2018;28:107–12.
   PubMed Web of Science ®Google Scholar
• Acharya S, Timilshina M, Jiang L, et al. Amelioration of experimental autoimmune encephalomyelitis and DSS induced colitis by NTG-A-009 through the inhibition of Th1 and Th17 cells differentiation. Sci Rep 2018;8:7799.
   PubMed Web of Science ®Google Scholar
• Park SW, Banskota S, Gurung P, et al. Synthesis and evaluation of 6-heteroarylamino-2,4,5-trimethylpyridin-3-ols as inhibitors of TNF-α-induced cell adhesion and inflammatory bowel disease. Medchemcomm 2018;9:1305–10.
   PubMed Web of Science ®Google Scholar
• Gautam J, Banskota S, Chaudhary P, et al. Antitumor activity of BJ-1207, a 6-amino-2,4,5-trimethylpyridin-3-ol derivative, in human lung cancer. Chem Biol Interact 2018;294:1–8.
   PubMed Web of Science ®Google Scholar
• Chaudhary CL, Gurung P, Jang S, et al. Synthesis, activity and mechanism of alkoxy-, carbamato-, sulfonamido-, thioureido-, and ureido-derivatives of 2,4,5-trimethylpyridin-3-ol against inflammatory bowel disease. J Enzyme Inhib Med Chem 2020;35:1–20.
   PubMed Web of Science ®Google Scholar
• Gurung P, Dahal S, Chaudhary P, et al. Potent inhibitory effect of BJ-3105, a 6-alkoxypyridin-3-ol derivative, on murine colitis is mediated by activating AMPK and inhibiting NOX. Int J Mol Sci 2020;21:3145.
   Web of Science ®Google Scholar
• Lowinger TB, Riedl B, Dumas J, Smith RA. Design and discovery of small molecules targeting raf-1 kinase. Curr Pharm Des 2002;8:2269–78.
   PubMed Web of Science ®Google Scholar
• Sae M, Yohei S, Masuo G, Kyoko NG. Antiproliferative and chemosensitizing effects of diarylheptanoids on intractable tumor cells. ACS Omega 2019;4:2053–62.
   Web of Science ®Google Scholar
• Matveenko M, Becker CFW. Synthesis approach to argpyrimidine as a tool for investigating nonenzymatic posttranslational modification of proteins. Synlett 2017;28:1950–5.
   Web of Science ®Google Scholar
• Friesner RA, Banks JL, Murphy RB, et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 2004;47:1739–49.
   PubMed Web of Science ®Google Scholar
• Mysinger MM, Carchia M, Irwin JJ, Shoichet BK. Directory of useful decoys, enhanced (DUD-E): better ligands and decoys for better benchmarking. J Med Chem 2012;55:6582–94.
   PubMed Web of Science ®Google Scholar
• Xu D, Meroueh SO. Effect of binding pose and modeled structures on SVMGen and GlideScore enrichment of chemical libraries. J Chem Inf Model 2016;56:1139–51.
   PubMed Web of Science ®Google Scholar
• Miller BR 3rd, McGee TD, Jr, Swails JM, et al, MMPBSA.py: an efficient program for end-state free energy calculations. J Chem Theory Comput 2012;8:3314–21.
   PubMed Web of Science ®Google Scholar
• Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006;66:11851–8.
   PubMed Web of Science ®Google Scholar
• Dhar DK, Naora H, Yamanoi A, et al. Requisite role of VEGF receptors in angiogenesis of hepatocellular carcinoma: a comparison with angiopoietin/Tie pathway. Anticancer Res 2002;22:379–86.
   PubMed Web of Science ®Google Scholar
• Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006;5:835–44.
   PubMed Web of Science ®Google Scholar
• Adorno-Cruz V, Kibria G, Liu X, et al. Cancer stem cells: targeting the roots of cancer, seeds of metastasis, and sources of therapy resistance. Cancer Res 2015;75:924–9.
   PubMed Web of Science ®Google Scholar
• Ayob AZ, Ramasamy TS. Cancer stem cells as key drivers of tumour progression. J Biomed Sci 2018;25:20.
   PubMed Web of Science ®Google Scholar
• Li J, Yu Y, Wang J, et al. Establishment of a novel system for the culture and expansion of hepatic stem-like cancer cells. Cancer Lett 2015;360:177–86.
   PubMed Web of Science ®Google Scholar
• Chen Y, Yu D, Zhang H, et al. CD133(+)EpCAM(+) phenotype possesses more characteristics of tumor initiating cells in hepatocellular carcinoma Huh7 cells. Int J Biol Sci 2012;8:992–1004.
   PubMed Web of Science ®Google Scholar
• Huang P, Zhuang B, Zhang H, et al. Hepatitis B virus X protein (HBx) is responsible for resistance to targeted therapies in hepatocellular carcinoma: ex vivo culture evidence. Clin Cancer Res 2015;21:4420–30.
   PubMed Web of Science ®Google Scholar
• Hawkins PC, Skillman AG, Warren GL, et al. Conformer generation with OMEGA: algorithm and validation using high quality structures from the Protein Databank and Cambridge Structural Database. J Chem Inf Model 2010;50:572–84.
   PubMed Web of Science ®Google Scholar
• Lee W, Lee S, Choi J, et al. Antithrombotic properties of JJ1, a potent and novel thrombin inhibitor. Sci Rep 2017;7:14862.
   PubMed Web of Science ®Google Scholar